Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing GlycoMimetics' Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML)

Ticker(s): GLYC

Who's the expert?

Institution: Fred Hutch Cancer Center/ University of Washington

Acting Instructor, Division of Hematology and Oncolgy, University of Washington School of Medicine.
Specializes in the treatment of acute myeloid leukemia (AML) and other myeloid malignancies.
Research focuses on studying how to bring cellular immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, to patients with AML.

Interview Goal

This conversation will focus on the Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee. It will explore overall survival distributions in AML.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.